MARKET

ASLN

ASLN

Aslan Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5499
+0.0149
+2.79%
Closed 18:28 08/09 EDT
OPEN
0.5800
PREV CLOSE
0.5350
HIGH
0.5800
LOW
0.5351
VOLUME
104.39K
TURNOVER
--
52 WEEK HIGH
3.360
52 WEEK LOW
0.3555
MARKET CAP
38.35M
P/E (TTM)
-1.0709
1D
5D
1M
3M
1Y
5Y
Aslan Pharmaceuticals Pte. Ltd. (Singapore, SG) Granted U.S. Patent #11,382,903 for Cancer therapy
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6615&f=G&l=50&d=PTXT&p=133&S1=20220712&OS=20220712&RS=20220712
Benzinga · 07/12 10:39
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 84 companies set new 52-week lows.
Benzinga · 06/09 17:21
ASLAN Pharmaceuticals Initiates Scientific Collaboration To Investigate The Distinct Role Of IL-13 Receptor Signaling In Atopic Dermatitis
role of the IL-13Ra1 subunit, distinct from the role of other pathway components, in Type 2-mediated inflammatory diseases, specifically atopic dermatitis (AD). The research collaboration will evaluate the role of
Benzinga · 06/07 11:19
BRIEF-Aslan Pharma Begins Scientific Collaboration To Investigate Il-13 Receptor Signaling In Atopic Dermatitis
reuters.com · 06/07 11:14
ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis
MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced th...
GlobeNewswire · 06/07 11:00
ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’
- Management to host the webinar in ASLAN’s A⁴ series on Wednesday, June 22, 2022, at 10:00am ETMENLO PARK, Calif. and SINGAPORE, June 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical...
GlobeNewswire · 06/06 11:00
ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference
MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that...
GlobeNewswire · 05/31 11:00
More
No Data
Learn about the latest financial forecast of ASLN. Analyze the recent business situations of Aslan Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ASLN stock price target is 5.50 with a high estimate of 8.00 and a low estimate of 3.000.
High8.00
Average5.50
Low3.000
Current 0.5499
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 36
Institutional Holdings: 26.37M
% Owned: 37.81%
Shares Outstanding: 69.74M
TypeInstitutionsShares
Increased
7
1.69M
New
4
104.07K
Decreased
10
2.95M
Sold Out
6
355.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Non-Executive Chairman/Independent Director
Andrew Howden
Chief Executive Officer/Director
Carl Firth
Chief Operating Officer
Kiran Asarpota
General Counsel
Ben Goodger
Other
Stephen Doyle
Other
Kenneth Kobayashi
Independent Director
Neil Graham
Independent Director
Robert Hoffman
Independent Director
Kathleen Metters
No Data
No Data
About ASLN
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy in autoimmune disease. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Webull offers kinds of Aslan Pharmaceuticals Ltd (ADR) stock information, including NASDAQ:ASLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASLN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASLN stock methods without spending real money on the virtual paper trading platform.